Back

Lakewood-Amedex reports Nu-3 MIC values 2-8 times below planned trial doses

Verifying
  • Lakewood-Amedex reported positive Nu-3 MIC data from recent diabetic-foot-infection isolates.
  • 2-8 times lower MIC values were recorded than planned clinical-trial doses.
  • Nu-3 is undergoing a Phase 2a trial, with topline data expected in first-quarter 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.